Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$69.60M$69.60Mderived+145.3% vs Q4 2023 Net Income-$78.00K-$78.00KderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$22,023,000+23.4% Operating Incomederived$3,634,000N/M Operating Cash Flowderived$198,000N/M Free Cash Flowderived$181,000N/M Margins · derivedGross margin31.6%−31.2 pt vs Q4 2023
Operating margin5.2%+43.8 pt vs Q4 2023
Net margin-0.1%+14.5 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 20, 2025 · 79 d after period end